TCGA-78-7154-01A-11R-2039-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.510
- MTORC1_SIGNALING+0.490
- MYC_TARGETS_V1+0.460
- E2F_TARGETS+0.430
- OXIDATIVE_PHOSPHORYLATION+0.400
- G2M_CHECKPOINT+0.370
- CHOLESTEROL_HOMEOSTASIS+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.330
- ESTROGEN_RESPONSE_EARLY+0.310
- FATTY_ACID_METABOLISM+0.310
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.450
- INTERFERON_ALPHA_RESPONSE-0.340
- INTERFERON_GAMMA_RESPONSE-0.330
- MYOGENESIS-0.250
- ALLOGRAFT_REJECTION-0.210
- APICAL_JUNCTION-0.180
- P53_PATHWAY-0.180
- INFLAMMATORY_RESPONSE-0.170
- IL6_JAK_STAT3_SIGNALING-0.130
- KRAS_SIGNALING_DN-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM5359435 | — | — | 0.845 |
| 2 | TCGA-39-5034-01A-01R-1443-07 | — | cohortA3 | 0.829 |
| 3 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.803 |
| 4 | TCGA-D8-A27W-01A-11R-A16F-07 | — | B | 0.799 |
| 5 | R265 | — | — | 0.794 |
| 6 | MDT-AP-0322 | Med | Medulloblastoma | 0.794 |
| 7 | TCGA-73-4676-01A-01R-1755-07 | — | cohortA1 | 0.794 |
| 8 | SRR4195661 | — | — | 0.788 |
| 9 | TCGA-77-7140-01A-41R-2045-07 | — | cohortSQ2 | 0.783 |
| 10 | MNG432 | — | — | 0.780 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.510 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.240 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |